BGM (BGM)

Its largest business area is associated with oxytetracycline, licorice and traditional Chinese medicine derivatives. Oxytetracycline is a widely known antibiotic compound used in pharmaceutical and veterinary contexts, while licorice-based preparations have applications across traditional medicine, health products and related formulations. These activities place BGM within regulated and quality-sensitive markets where manufacturing standards, raw material sourcing and customer qualification are central to commercial performance.

The company also participates in the heparin supply chain through crude heparin sodium. Heparin is an important anticoagulant used in medical settings, and crude heparin serves as an upstream material that requires further processing before finished pharmaceutical use. This segment is tied to biological extraction, traceability and stringent quality controls. BGM’s sausage casing operations are related to animal by-product processing and provide an additional line of business outside its core pharmaceutical and health product focus.

BGM is distinctive because it combines biotechnology, extraction-based manufacturing and traditional health product categories rather than operating as a single-product drug developer. Its revenue mix reflects demand from pharmaceutical, medical health and related industrial customers. The company’s prospects depend on product quality, regulatory compliance, input costs, manufacturing efficiency and demand for its antibiotic, licorice, heparin and casing-related products.